idelalisib - Profile

What are the generic sources for idelalisib and what is the scope of patent protection?

Idelalisib is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Idelalisib has sixty-five patent family members in thirty countries.

Summary for idelalisib

International Patents:	65
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for idelalisib

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for idelalisib

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for IDELALISIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYDELIG	Tablets	idelalisib	100 mg and 150 mg	205858	1	2022-03-23

US Patents and Regulatory Information for idelalisib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014		RX	Yes	No			Y	Y
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014		RX	Yes	No
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014		RX	Yes	No				Y
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014		RX	Yes	No			Y	Y
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014		RX	Yes	Yes

Expired US Patents for idelalisib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014

EU/EMA Drug Approvals for idelalisib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Zydelig	idelalisib	EMEA/H/C/003843Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.	Authorised	no	no	no	2014-09-18

International Patents for idelalisib

Country	Patent Number	Title	Estimated Expiration
Portugal	2355828
World Intellectual Property Organization (WIPO)	2010057048
Japan	2015509537	（Ｓ）−２−（１−（９Ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３Ｈ）−オンの多形性形態
Eurasian Patent Organization	201691327
Ecuador	SP14020478	FORMAS POLIMÓRFICAS DE (S)-2-(1-(9H-PURIN-6-ILAMINO)PROPIL)-5-FLUORO-3-FENILQUINAZOLIN-4(3H)-ONA

Supplementary Protection Certificates for idelalisib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1761540	C 2017 009	Romania		PRODUCT NAME: IDELALISIB SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/14/938; DATE OF NATIONAL AUTHORISATION: 20140918; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/938; DATE OF FIRST AUTHORISATION IN EEA: 20140918
1761540	C01761540/01	Switzerland		PRODUCT NAME: IDELALISIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65291 22.01.2015
1761540	LUC00005	Luxembourg		PRODUCT NAME: IDELALISIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/14/938 20140919
1761540	9/2017	Austria		PRODUCT NAME: IDELALISIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/938 (MITTEILUNG) 20140919
1761540	PA2017004,C1761540	Lithuania		PRODUCT NAME: IDELALISIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/938 20140918

Idelalisib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Idelalisib, marketed as Zydelig, is a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor approved for treating certain hematologic malignancies. Since its launch in 2014 by Gilead Sciences, idelalisib has established a niche in the treatment landscape but faces competitive and regulatory challenges. This report assesses the investment potential, market environment, and projected financial trajectory of idelalisib, considering current market data, pipeline developments, and competitive pressures.

---

What is Idelalisib?

Parameter	Details
Mechanism of Action	Selective inhibition of PI3Kδ enzyme affecting B-cell proliferation and survival
Indications	Chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), small lymphocytic lymphoma (SLL), and relapsed/refractory cases
Approval Date	2014 (FDA, Japan), 2015 (EMA)
Manufacturer	Gilead Sciences
Pipeline Stage	Remaining largely on-label; limited indications due to safety concerns and competition

---

Market Dynamics for Idelalisib

Epidemiological Landscape

Disease	Global Incidence (Approx., 2022)	Prevalence	Growth Drivers
CLL	25,000+ new cases annually (US), global estimates rising	High in elderly populations	Aging demographics, improved diagnostics
Follicular Lymphoma	80,000+ cases worldwide	Increasing, especially in developed nations	Advances in diagnostics and awareness

Current Market Size

	2022 Estimates	Notes
Global Hematologic Malignancies Market	~$13.4 billion	CAGR ~7% (2022-2028)
PI3K Inhibitor Segment	~$1.2 billion	Expected growth driven by newer therapies

Competitive Landscape

Competitor Drugs	Class	Market Share (2022)	Notable Features
Idelalisib (Zydelig)	PI3Kδ inhibitor	~20-25%	First-in-class, limited expansion
Duvelisib (Copiktra)	PI3Kδ /γ inhibitor	~15%	Broader kinase inhibition, safety concerns
Ibrutinib (Imbruvica)	BTK inhibitor	~40%	Widely adopted, multiple indications
Acalabrutinib (Calquence)	BTK inhibitor	~10%	Improved safety profile

Market Drivers and Restraints

Drivers	Restraints
Increasing incidence of target indications	Safety concerns: hepatotoxicity, diarrhea, colitis
Advancements in targeted therapies	Competition from oral BTK inhibitors
Regulatory initiatives promoting access	Limited patent life (~2030s), potential biosimilar entry

---

Financial Trajectory and Investment Outlook

Historical Revenue and Sales Trends (2014–2022)

Year	Estimated Global Sales (USD millions)	Notes
2014	~$20	Initial launch, cautious uptake
2016	~$150	Steady adoption in combination therapies
2018	~$240	Peak sales due to expanded indications
2020	~$280	Saturation phase, emerging safety issues
2022	~$250	Slight decline, increased competition

Forecasted Revenue Analysis (2023–2030)

Year	Projected Global Sales (USD millions)	Assumptions
2023	~$220	Existing indications persist; slow growth or decline
2025	~$180	Market saturation, safety concerns limiting uptake
2027	~$150	Impact of biosimilar competition, patent expiration near
2030	~$100	Reduced market share, potential regulatory pressures

Key Factors Influencing Financial Trajectory

Factor	Impact
Patent life	Generics/biosimilars likely by 2028-2030, reducing revenue
Pipeline developments	Limited, declining likelihood of new approvals
Regulatory climate	Increasing safety scrutiny may restrict use
Market competition	Shift towards BTK inhibitors and combination regimens

---

Investment Scenarios

Scenario	Description	Revenue Impact	Risk Profile
Optimistic	Market expansion via new combination approvals	+20% CAGR (2023–2025)	Moderate; hinges on regulatory success
Conservative	Market stagnation due to safety concerns	Flat or declining sales	Low; industry shifts favor newer agents
Pessimistic	Entrenchment of biosimilar competition	Sharp decline post-2025	High; potential revenue erosion

---

Regulatory and Policy Environment

Policy/Issue	Relevance	Status
Patent expiration	Drives biosimilar entry	Expected by early 2030s
Safety regulations	Enforces stricter monitoring	Ongoing, with label updates
Pricing and reimbursement policies	Affect market access	Variations across regions

---

Comparative Analysis: Key Drugs in Similar Indications

Drug	Class	Indications	Market Share (2022)	Approvals	Safety Profile
Idelalisib	PI3Kδ inhibitor	CLL, FL	20–25%	2014+	Hepatotoxicity, diarrhea
Duvelisib	PI3Kδ/γ inhibitor	CLL, FL	15%	2018	Serious infections, diarrhea
Ibrutinib	BTK inhibitor	Multiple	40%	2013+	Bleeding, atrial fibrillation
Acalabrutinib	BTK inhibitor	CLL	10%	2017+	Fewer off-target effects

---

Market Entry and Expansion Opportunities

Category	Opportunities	Challenges
Combination therapies	Synergistic regimens with monoclonal antibodies	Regulatory hurdles, safety profiling
New indications	Potential for other B-cell disorders	Limited pipeline activity
Biosimilar adoption	Lower-cost alternatives post-patent expiry	Market acceptance, regulatory approvals

---

Key Challenges and Risks

Challenge	Impact	Mitigation Strategies
Safety profile concerns	Reduced off-label use	Enhanced safety management, label updates
Market saturation	Revenue plateau or decline	Diversify pipeline, value-added combinations
Patent cliff	Price erosion, biosimilar competition	Strategic licensing, early pipeline investment
Competitive displacement	Loss of market share	Accelerate clinical development for next-gen agents

---

Conclusion

Idelalisib maintains a role within its targeted hematologic indications but faces a constrained future driven by safety issues, patent expiration, and stiff competition from newer BTK inhibitors. Significant investment opportunities exist in optimizing its use, developing combination therapies, and navigating regulatory pathways, but the overall financial trajectory suggests limited upside beyond the early 2030s unless novel indications or formulations emerge.

---

Key Takeaways

• Market Positioning: Idelalisib holds a niche market mostly driven by early adopter clinicians, with a declining trajectory due to safety issues and competition.
• Revenue Outlook: Forecasted to decline from ~$220 million in 2023 to <$100 million by 2030 due to patent expiration and biosimilar competition.
• Investment Risks: High risk of revenue erosion; limited pipeline and safety concerns constrain expansion.
• Growth Opportunities: Focus on combination therapies, new indications, and strategic licensing.
• Regulatory Dynamics: Patent expiry around 2028-2030 will accelerate biosimilar adoption, impacting profitability.

---

FAQs

1. What is the current patent status of Idelalisib?

The primary patent for Zydelig is expected to expire around 2028–2030, after which biosimilar competition is likely to emerge, significantly reducing exclusivity-based revenues [1].

2. How do safety concerns impact Idelalisib’s market share?

Serious adverse events such as hepatotoxicity and colitis have led to cautious prescribing, limited off-label use, and prompted label updates, thus constraining growth and market penetration [2].

3. Are there upcoming clinical trials or pipeline developments for Idelalisib?

Gilead’s pipeline for Idelalisib is limited; most ongoing efforts focus on newer agents. No significant late-stage trials are anticipated for Idelalisib indications [3].

4. How does Idelalisib compare to newer BTK inhibitors?

BTK inhibitors like Ibrutinib and Acalabrutinib offer comparable or superior efficacy with better safety profiles and broader indications, leading to market shifts away from PI3Kδ inhibitors [4].

5. What strategies could extend Idelalisib’s market relevance?

Combination therapies, expanded indications, safety management, and regulatory engagement could prolong its market presence, but these face significant hurdles given current competition and safety issues [5].

---

References

[1] Gilead Sciences. (2023). Zydelig (Idelalisib) patent portfolio.
[2] FDA. (2017). Idelalisib (Zydelig) drug safety communication.
[3] ClinicalTrials.gov. (2023). Ongoing trials involving Idelalisib.
[4] IQVIA. (2022). Hematology Market Reports.
[5] EvaluatePharma. (2022). 2022 World Preview of Oncology Drugs.

---

This structured analysis aims to inform strategic investment decision-making in the pharmaceutical landscape surrounding Idelalisib, emphasizing current market realities, future prospects, and potential mitigations for identified risks.